Roth Keeps TG Therapeutics (TGTX) as 'Focus Pick' Following ASCO Presentations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Roth Positive on TG Therapeutics (TGTX) into EHA Presentation
June 11, 2014 7:56 AM EDTRoth Capital affirms its Focus Pick rating and $15 target price on TG Therapeutics, Inc. (Nasdaq: TGTX) ahead of the pharma's presentation at EHA over the weekend.
Analyst Joseph Pantginis is looking for stronger visibility from the TG-1101/Imbruvica Phase II in B-cell malignancies. The analyst comments, We expect TG to shine this weekend with what we have called the "match... More
TG Therapeutics (TGTX) Updates on TG-1101 Phase I Ahead of ASCO
May 30, 2014 1:56 PM EDTTG Therapeutics, Inc. (Nasdaq: TGTX) announced clinical results from its ongoing Phase I single agent study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody and from its ongoing first-in-human Phase I single agent study of TGR-1202, the Company's oral, once-daily, PI3K delta inhibitor. Data from these Phase I studies are being presented today at poster sessions during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, with both posters selected for discussion later in the day during oral Poster Highlight sessions.
Today's poster presentations include data from 35... More
